Haemonetics (HAE) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Haemonetics (HAE) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.1 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago.
Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations
Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials for hereditary angioedema patient populations. Key catalysts include RAPIDe-3 phase 3 topline data in Q4 2025 for on-demand HAE and CHAPTER-3 prophylaxis data expected in the second half of 2026. Deucrictibant's unique oral formulation and dual-use potential could capture significant market share in the $19.68B HAE market if trials are successful.
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success
Pharvaris is a late-stage biopharma that specializes in the treatment of hereditary angioedema (HAE). They have only one drug in their pipeline, deucrictibant, of which they are making two oral formulations: an immediate-release capsule for acute attacks and a daily extended-release tablet. Phase 3 results for the immediate-release capsules (Rapide-3) are expected in Q4 2025.
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY's convenience and rapid symptom relief position it for strong market adoption, with a $4 billion HAE market opportunity and potential to shift on-demand market share. Global expansion is underway, with seven regulatory submissions, and if approved for these territories, it could increase the amount of revenues that are to be generated.
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.
Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q4 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Olga Guyette – Vice President-Investor Relations & Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Rohin Patel – JPMorgan Marie Thibault – BTIG Mike Matson – Needham & Company Andrew Cooper – Raymond James Joanne Wuensch – Citi Anthony Petrone – Mizuho Financial Group Michael Petusky – Barrington Research Craig Bijou – Bank of America Securities Operator Good day, and thank you for standing by. Welcome to the Q4 2025 Haemonetics Corporation Earnings Conference Call.
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.90 per share a year ago.
Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
